
Claims:

1. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis in a patient in need thereof, wherein the compound in the medicament is to be administered at a daily amount ranging from about 20 mg to about 300 mg or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:




2. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount ranging from about 25 mg to about 150 mg or a pharmaceutically acceptable salt thereof.
3. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount of about 90 mg or a pharmaceutically acceptable salt thereof.
4. The use of any one of claims 1-3, wherein the medicament is to be administered only once per day.
5. The use of any one of claims 1-4, wherein the medicament is to be administered twice per day.
6. The use of claim 1, wherein the medicament is to be orally administered twice per day as a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of about 45 mg or a pharmaceutically acceptable salt thereof.
7. The use of any one of claims 1-6, wherein the patient has recently consumed food prior to receiving the medicament.
8. The use of any one of claims 1-6, wherein the patient has consumed food within 1 hour prior to receiving the medicament.
9. The use of any one of claims 1-6, wherein the patient has not recently consumed food prior to receiving the medicament.

10. The use of any one of claims 1-6, wherein the patient has not consumed food within 1 hour prior to receiving the medicament.

11. The use of any one of claims 1-6, wherein the patient consumes a meal within 1 hour of receiving the medicament.

12. The use of any one of claims 1-6, wherein the medicament is to be administering at a time when the patient consumes a meal.

13. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis, wherein the medicament is to be orally administered to a patient in need thereof two times per day as a unit dosage containing the compound in an amount ranging from about 25 mg to about 50 mg or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:



.

14. The use of claim 13, wherein the unit dosage is to be administered to the patient in the form of two unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

15. The use of claim 13, wherein the unit dosage is to be administered to the patient in the form of a single unit formulation containing compound of Formula I or a pharmaceutically acceptable salt thereof.

16. The use of any one of claims 13-15, wherein the unit formulation(s) are in the form of a tablet or capsule.

17. The use of any one of claims 13-16, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.


18. The use of any one of claims 13-17, wherein a first unit dosage is to be administered to the patient in the morning, and a second unit dosage is to be administered to the patient in the evening.

19. The use of any one of claims 13-18, wherein the patient has consumed food within 2 hours prior to receiving the unit dosage.

20. The use of any one of claims 13-18, wherein the patient has consumed food within 1 hour prior to receiving the unit dosage.

21. The use of any one of claims 13-18, wherein the patient consumes food within 30 minutes of receiving the unit dosage.

22. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis, wherein the medicament is to be orally administered to a patient in need thereof twice daily as a unit dosage containing the compound in an amount of about 45 mg or a pharmaceutically acceptable salt thereof, wherein the patient consumes a meal within about 1 hour of the administration, and Formula I is represented by:



.

23. The use of claim 22, wherein the unit dosage is to be administered to the patient in the form of one or more unit formulations containing the compound of Formula I or a pharmaceutically acceptable salt thereof.

24. The use of claim 23, wherein the unit formulation(s) are in the form of a tablet or capsule.

25. The use of any one of claims 22-24, wherein the medicament is to be administered at the time the patient consumes a meal.

26. The use of any one of claims 22-25, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.

27. The compound for use of any one of claims 22-26, wherein a first unit dosage is administered to the patient in the morning, and a second unit dosage is administered to the patient in the evening.

28. The compound for use of any one of claims 22-24, wherein a first unit dosage is administered to the patient at the time the patient consumes a breakfast meal in the

morning, and a second unit dosage is administered to the patient at the time the patient consumes a dinner meal in the evening.

29. The compound for use of any one of claims 1-28, wherein the multiple sclerosis is relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, or progressive-relapsing multiple sclerosis.

30. The compound for use of any one of claims 1-28, wherein the multiple sclerosis is relapsing multiple sclerosis.